Isracann Biosciences Inc.
CCSE:IPOTShare Statistics
As of August 31, 2022, Isracann Biosciences Inc. has 162.97M shares outstanding.
| Shares Outstanding | 162.97M |
Valuation Ratios
These figures are as of August 31, 2022.
| PB Ratio | 50.86 |
| P/TBV Ratio | -1.83 |
| P/FCF Ratio | -4.07 |
| P/OCF Ratio | -4.07 |
Financial Position
As of August 31, 2022, Isracann Biosciences Inc. maintains a current ratio of 0.30, meaning it holds 0.3x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 0.30 |
| Quick Ratio | 0.27 |
Financial Efficiency
Over the twelve months ended August 31, 2022, Isracann Biosciences Inc. posted a negative return on equity (ROE) of -252.29, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -113.98, reflecting losses generated across the asset base.
| Return on Equity (ROE) | -252.29 |
| Return on Assets (ROA) | -113.98 |
Dividends & Yields
These figures cover the twelve months ended August 31, 2022. Free cash flow yield is negative at -24.55: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -4.32, meaning Isracann Biosciences Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.
| Shareholder Yield | -4.32 |
| FCF Yield | -24.55 |
Stock Splits
Isracann Biosciences Inc.'s most recent stock split took place on October 17, 2019 with a 3:1 split ratio.
| Last Split Date | 10/17/2019 |
| Split Ratio | 3:1 |
Scores
As of August 31, 2022, Isracann Biosciences Inc. has an Altman Z-Score of -340.45, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -340.45 |